Identification of Sestrin3 Involved in the In Vitro Resistance of Colorectal Cancer Cells to Irinotecan

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 May 15

PMID 25973791

Citations 2

Authors

Seung Ho Choi

Hye Kyung Hong

Yong Beom Cho

Woo Yong Lee

Hae Yong Yoo

Affiliations

Soon will be listed here.

Abstract

Irinotecan, an analogue of camptothecin, is frequently used as a single agent or in combination with other anticancer drugs for the treatment of colorectal cancer. However, the drug resistance of tumors is a major obstacle to successful cancer treatment. In this study, we established that cells acquire chronic resistance to irinotecan. We profiled their differential gene expression using microarray. After gene ontology (GO) and KEGG pathway analysis of the microarray data, we specifically investigated whether Sestrin3 could decrease irinotecan resistance. Our results revealed that Sestrin3 enhanced the anticancer effect of irinotecan in vitro in LoVo cells that had acquired resistance to irinotecan. Irinotecan-resistant LoVo cells showed lower reactive oxygen species (ROS) production than their irinotecan-sensitive parental cells. ROS production was increased by Sestrin3 knockdown in irinotecan-resistant LoVo cells. Our results indicate that Sestrin3 might be a good target to develop therapeutics that can help to overcome resistance to irinotecan.

Citing Articles

The functions and roles of sestrins in regulating human diseases.

Chen Y, Huang T, Yu Z, Yu Q, Wang Y, Hu J Cell Mol Biol Lett. 2022; 27(1):2.

PMID: 34979914 PMC: 8721191. DOI: 10.1186/s11658-021-00302-8.

Gene promoter and exon DNA methylation changes in colon cancer development - mRNA expression and tumor mutation alterations.

Molnar B, Galamb O, Peterfia B, Wichmann B, Csabai I, Bodor A BMC Cancer. 2018; 18(1):695.

PMID: 29945573 PMC: 6020382. DOI: 10.1186/s12885-018-4609-x.

References

Kelley L, MacCallum R, STERNBERG M . Enhanced genome annotation using structural profiles in the program 3D-PSSM. J Mol Biol. 2000; 299(2):499-520. DOI: 10.1006/jmbi.2000.3741. View

Xu Y, Villalona-Calero M . Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol. 2002; 13(12):1841-51. DOI: 10.1093/annonc/mdf337. View

Behrend L, Henderson G, Zwacka R . Reactive oxygen species in oncogenic transformation. Biochem Soc Trans. 2003; 31(Pt 6):1441-4. DOI: 10.1042/bst0311441. View

Budanov A, Sablina A, Feinstein E, Koonin E, Chumakov P . Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science. 2004; 304(5670):596-600. DOI: 10.1126/science.1095569. View

Pelicano H, Carney D, Huang P . ROS stress in cancer cells and therapeutic implications. Drug Resist Updat. 2004; 7(2):97-110. DOI: 10.1016/j.drup.2004.01.004. View

Irani K, Xia Y, Zweier J, Sollott S, Der C, Fearon E . Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science. 1997; 275(5306):1649-52. DOI: 10.1126/science.275.5306.1649. View

Altschul S, Madden T, Schaffer A, Zhang J, Zhang Z, Miller W . Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997; 25(17):3389-402. PMC: 146917. DOI: 10.1093/nar/25.17.3389. View

Shaw R, Cantley L . Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006; 441(7092):424-30. DOI: 10.1038/nature04869. View

Alexandrova A, Kopnin P, Vasiliev J, Kopnin B . ROS up-regulation mediates Ras-induced changes of cell morphology and motility. Exp Cell Res. 2006; 312(11):2066-73. DOI: 10.1016/j.yexcr.2006.03.004. View

10.

Kopnin P, Agapova L, Kopnin B, Chumakov P . Repression of sestrin family genes contributes to oncogenic Ras-induced reactive oxygen species up-regulation and genetic instability. Cancer Res. 2007; 67(10):4671-8. PMC: 2657553. DOI: 10.1158/0008-5472.CAN-06-2466. View

11.

Wolpin B, Mayer R . Systemic treatment of colorectal cancer. Gastroenterology. 2008; 134(5):1296-310. PMC: 2528832. DOI: 10.1053/j.gastro.2008.02.098. View

12.

Budanov A, Karin M . p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell. 2008; 134(3):451-60. PMC: 2758522. DOI: 10.1016/j.cell.2008.06.028. View

13.

Nogueira V, Park Y, Chen C, Xu P, Chen M, Tonic I . Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell. 2008; 14(6):458-70. PMC: 3038665. DOI: 10.1016/j.ccr.2008.11.003. View

14.

Mayer R . Targeted therapy for advanced colorectal cancer--more is not always better. N Engl J Med. 2009; 360(6):623-5. DOI: 10.1056/NEJMe0809343. View

15.

Pouyet L, Carrier A . Mutant mouse models of oxidative stress. Transgenic Res. 2009; 19(2):155-64. DOI: 10.1007/s11248-009-9308-6. View

16.

Lee J, Budanov A, Park E, Birse R, Kim T, Perkins G . Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies. Science. 2010; 327(5970):1223-8. PMC: 2866632. DOI: 10.1126/science.1182228. View

17.

Cunningham D, Atkin W, Lenz H, Lynch H, Minsky B, Nordlinger B . Colorectal cancer. Lancet. 2010; 375(9719):1030-47. DOI: 10.1016/S0140-6736(10)60353-4. View

18.

Chen C, Jeon S, Bhaskar P, Nogueira V, Sundararajan D, Tonic I . FoxOs inhibit mTORC1 and activate Akt by inducing the expression of Sestrin3 and Rictor. Dev Cell. 2010; 18(4):592-604. PMC: 3031984. DOI: 10.1016/j.devcel.2010.03.008. View

19.

Budanov A, Lee J, Karin M . Stressin' Sestrins take an aging fight. EMBO Mol Med. 2010; 2(10):388-400. PMC: 3166214. DOI: 10.1002/emmm.201000097. View

20.

Kim J, Kundu M, Viollet B, Guan K . AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011; 13(2):132-41. PMC: 3987946. DOI: 10.1038/ncb2152. View